Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - VIROPHARMA INC | a13-2139_2ex99d1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 7, 2013
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
0-021699 |
|
23-2789550 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
|
730 STOCKTON DRIVE, EXTON, PENNSYLVANIA |
|
19341 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(610) 458-7300
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 7.01.Regulation FD Disclosure.
On January 7, 2013, ViroPharma Incorporated (the “Company”), issued a press release commenting on an unaudited 2012 Cinryze net sales estimate, 2013 net product sales and expense guidance. The full text of the press release is furnished as Exhibit 99.1 attached hereto.
Item 9.01Financial Statements and Exhibits.
The following exhibits are attached to this Form 8-K:
|
(d) |
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
|
|
99.1 |
|
Press release dated January 7, 2013. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VIROPHARMA INCORPORATED | |
|
|
| |
|
|
| |
|
Date: January 7, 2013 |
By: |
/s/ J. Peter Wolf |
|
|
|
J. Peter Wolf |
|
|
|
Vice President, General Counsel and |
|
|
|
Secretary |